By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is divided on Novo Nordisk's Wegovy pill, with concerns about simultaneous margin compression from Indian patent cliffs and U.S. price cuts, and the potential impact of Eli Lilly's competing oral GLP-1 candidate.
Risk: Simultaneous margin compression from Indian patent cliffs and U.S. price cuts before volume lift from pills materializes
Opportunity: Potential expansion of GLP-1 penetration with oral Wegovy
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Wall Street likes stories, and a big one today is the huge demand for GLP-1 weight-loss drugs.
Novo Nordisk got off to an early lead, but Eli Lilly is now the most noted name in the space.
Novo Nordisk's GLP-1 new pill option could be an important turning point for the company as it looks to better compete with Eli Lilly.
The pharmaceutical industry is highly competitive and driven by innovation. Those two facts couldn't be on any clearer display than in the competition between Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) in the newly created GLP-1 weight-loss space. While Eli Lilly looks like the winner right now, Novo Nordisk's Wegovy pill is performing better than expected. That's important, and it could turn the stock into a long-term buy for dividend lovers.
Novo Nordisk was first to market with a GLP-1 weight-loss drug. The only problem is that it couldn't keep up with the demand for its Wegovy shot. That allowed compounders to enter the U.S. market for the drug, limiting the company's growth opportunities. It also gave competitor Eli Lilly a big opening when it launched its own GLP-1 options, Mounjaro and Zepbound.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Eli Lilly's drugs were also more effective, so the company's financial performance was strong while Novo Nordisk was basically left playing catch-up. Investors reacted by dumping Novo Nordisk and buying Eli Lilly. The difference couldn't be more stark, with Novo Nordisk down 40% over the past three years and Eli Lilly up over 150%.
However, there was an important change at the start of 2026. That was when Novo Nordisk released a pill version of Wegovy. Many consumers prefer pills over shots, so this development really opens GLP-1 drugs to more customers. That's been proven, with the pharmaceutical company seeing even faster growth with the pill than with the shot. And the pill doesn't appear to be cannibalizing the shot, so the GLP-1 market is indeed expanding. This is even better performance than the company had hoped for, with the pill generating 1.3 million prescriptions in the first quarter alone. One month later, when the company provided its first-quarter earnings results, the number of prescriptions had catapulted to two million.
That said, Novo Nordisk warned investors that 2026 would be a hard year. Wegovy is losing patent protection in India, which is putting pressure on the company's sales in that large market. And Novo Nordisk agreed to cut prices in the U.S. market, which is also weighing on the top line. Management expects volume to offset price over the long term as the Wegovy pill draws in more customers to the GLP-1 space. Given the pill's early success, that storyline sounds increasingly likely.
There's just one problem: the healthcare sector is intensely competitive. Eli Lilly has also come out with a GLP-1 pill, but it is a different drug from its shot. And it appears that Novo Nordisk's pill is more effective, giving it both a marketing and effectiveness edge. That doesn't guarantee Novo Nordisk's success, but it does suggest that investors may be ignoring an important opportunity.
If you are a long-term dividend investor, Novo Nordisk's historically high 3.9% yield should be on your radar. That's doubly true when you consider that the payout ratio is a very reasonable 40% or so. By comparison, Eli Lilly's yield is a tiny 0.6%.
Buying Novo Nordisk comes with risk, as does any investment in a highly competitive industry. However, the early success of its Wegovy pill suggests that Wall Street may be missing the long-term opportunity the company has ahead as it works through a transition year. If you don't mind being paid well to wait for better days, strong sales of Novo Nordisk's weight-loss pills are the sign that things aren't nearly as bad as investors seem to believe.
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,191! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,258,838!
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 6, 2026. *
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Novo Nordisk can extend its growth via Wegovy's pill, but upside is contingent on durable demand, price discipline, and competition—factors the article glosses over."
News that Novo's Wegovy pill is accelerating faster than expected is a meaningful positive signal for Novo Nordisk, but it isn't a free pass. The article underestimates how price cuts, generic competition in India, and payer headwinds could cap near-term growth. The real test is whether the pill expands GLP-1 penetration enough to offset U.S. price discipline and ongoing Lilly competition, while maintaining margins as manufacturing and marketing spend rise. If the pill becomes a durable driver of volume, Novo could sustain a multi-year ramp, but the upside hinges on regulatory clearance, real-world adherence, and global access dynamics, not just prescription counts.
The strongest counter is that the pill narrative may overstate growth. A faster switch to pills could be offset by price pressure, regulatory hurdles, or slower adoption outside the U.S.; and Lilly remains a threat with its own GLP-1 offerings and a broader pipeline that could erode Novo's advantage.
"The transition to an oral delivery model for Wegovy represents a structural pivot that will expand the total addressable market beyond the capacity of injectable-only competitors."
The market is currently mispricing NVO by focusing on short-term headwinds—specifically, Indian patent expirations and U.S. pricing pressure—while ignoring the massive TAM expansion triggered by the oral Wegovy formulation. Oral delivery is the 'holy grail' for GLP-1s, removing the friction of injections and significantly lowering the barrier to entry for the broader, non-obese, or early-stage overweight population. With a 3.9% yield and a 40% payout ratio, NVO is providing a value floor that LLY lacks. If the pill sustains its current prescription velocity, the margin compression from price cuts will be more than offset by volume-driven economies of scale in manufacturing.
The thesis relies on NVO maintaining a clinical edge in oral efficacy, but if LLY’s pipeline delivers superior oral bioavailability or fewer gastrointestinal side effects, NVO’s current pill success becomes a temporary bridge to obsolescence.
"NVO's pill success is real but doesn't automatically offset 2026 price/patent headwinds—the margin bridge from volume growth is unproven and the article assumes it without showing the math."
The article conflates early prescription volume with durable competitive advantage. Yes, 2M Wegovy pill prescriptions in Q1 2026 is impressive, but the article glosses over three critical headwinds: (1) Eli Lilly's pill is 'different' but we have no efficacy data comparing them head-to-head; (2) NVO faces 2026 price compression in the US *and* India patent cliff simultaneously—a margin squeeze that pill volume alone may not offset; (3) the 3.9% yield is attractive only if earnings don't crater. The article assumes volume growth saves margins, but doesn't quantify the math.
If Lilly's pill proves non-inferior or superior in real-world use, NVO's 'effectiveness edge' evaporates overnight, and the stock re-rates lower despite volume growth. Dividend sustainability depends on EBITDA holding up through the transition—no guarantee.
"Near-term patent and pricing headwinds plus Lilly's competing oral will likely outweigh the Wegovy pill's early momentum for NVO shares."
The article positions Novo Nordisk's Wegovy oral as a game-changer that could reverse three years of 40% underperformance versus Eli Lilly. Yet it glosses over the 2026 revenue hit from Indian patent loss and mandated U.S. price cuts, both of which arrive before the pill's volume ramp can fully compensate. Lilly's separate oral GLP-1 candidate also remains unaddressed, leaving open the possibility that any first-mover edge in pills proves temporary. Supply constraints, payer pushback, and potential market saturation in the GLP-1 class add further execution risk not captured by early prescription counts alone.
Prescription data already show the pill expanding the overall market without cannibalizing shots, and if volume offsets price cuts as guided, the 3.9% yield could support a re-rating once 2026 clears.
"Margin and competitive risk from 2026 price cuts and patent cliffs could negate any volume-led upside from the oral pill, especially if Lilly's oral shows superior real-world efficacy."
Responding to Gemini: the allure of an oral Wegovy is clear, but the math isn’t safe. Indian patent cliff + U.S. price cuts will hit margins before any volume lift from pills materializes, and the yield floor assumes EBITDA resilience that’s unproven through the transition. If Lilly’s oral enters with better bioavailability or fewer GI side effects, NVO’s edge could evaporate quickly, undermining the dividend support you rely on.
"The dividend yield is not a safety net but a potential liability if margin compression from patent cliffs and pricing pressure forces a capital allocation pivot."
Gemini, your 'value floor' argument ignores the volatility of the underlying cash flows. Relying on a 3.9% yield while NVO faces a simultaneous margin squeeze from Indian patent cliffs and US price caps is dangerous. If EBITDA contracts as expected in 2026, the dividend payout ratio will spike, potentially forcing a cut. You are treating a growth stock like a utility, ignoring that pharmaceutical R&D spending must accelerate to defend against Lilly’s superior oral bioavailability.
"NVO's dividend safety hinges on management's 2026 EBITDA guidance, not just pill prescription velocity."
ChatGPT and Gemini are both correct that margins face 2026 compression, but neither quantifies the breakeven. If NVO's pill reaches 4M+ prescriptions by late 2026, manufacturing scale could offset 15–20% price erosion. The real question: does management guide to flat or positive EBITDA through 2026? Without that disclosure, the dividend cut risk is real, but so is the possibility that volume math works. Lilly's oral remains the wildcard—efficacy parity kills NVO's thesis.
"India and U.S. 2026 shocks create a margin hole volume cannot close before Lilly's oral arrives."
Claude's 4M-prescription breakeven math underplays how India's 2026 patent cliff and simultaneous U.S. mandated cuts compound before any manufacturing scale materializes. Even if volume lifts EBITDA, the required acceleration in R&D to counter Lilly's oral bioavailability edge will widen the cash-flow gap, making the 3.9% yield far less stable than assumed. Supply constraints on the pill itself remain the unaddressed limiter.
The panel is divided on Novo Nordisk's Wegovy pill, with concerns about simultaneous margin compression from Indian patent cliffs and U.S. price cuts, and the potential impact of Eli Lilly's competing oral GLP-1 candidate.
Potential expansion of GLP-1 penetration with oral Wegovy
Simultaneous margin compression from Indian patent cliffs and U.S. price cuts before volume lift from pills materializes